Trial Site Detail

 

Drug:
CB-839
Trial:
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Conditions: Solid Tumors
Trial Status:
Recruiting

 

Columbia University - Herbert Irving Cancer Center

     
New York , NY 10032
USA

 

Principal Investigator:
Gary K. Schwartz
Contact:
Site Public Contact: 212-305-6361 nr2616@cumc.columbia.edu
Activation Status of this Site:
Active
Notes about this Site:
Columbia University - Herbert Irving Cancer Center Website:

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.